Track topics on Twitter Track topics that are important to you
GAZYVATM (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
Created at Glycart Biotechnology, Gazyva (obinutuzumab), a type II bioengineered anti-CD20 humanized IgG1 monoclonal, has been developed by Biogen Idec and Roche subsidiaries Genentech and Chugai Pharmaceutical. As with Rituxan® (rituximab), Zevalin® (ibritumomab tiuxetan) and Bexxar® (tositumomab), Gazyva binds to CD20, an activated-glycosylated phosphoprotein target expressed on the surface of all B-cells, causing cell death by apoptosis. It is indicated for use, in combination with chlorambucil, for the treatment of previously untreated CLL.
For full details open - http://www.gazyva.com/hcp
Adapted from - Thomson Reuters Cortellis Competitive Intelligence